Authors: Kárason KT, Vo D, Grauslund J, Rasmussen ML.
Geographical coverage: The USA, the UK, Denmark, Germany, France and Italy
Sector: Service delivery
Sub-sector: Screening, imaging
Equity focus: Not reported
Study population: Patients with diabetic retinopathy
Review type: Other review
Quantitative synthesis method: Not applicable
Qualitative synthesis method: Narrative synthesis
Background: Diabetic retinopathy (DR) is a leading cause of irreversible vision loss worldwide. Screening for DR is recommended to detect sight-threatening complications prior to visual loss. Early Treatment Diabetic Retinopathy Study (ETDRS) seven standard field (7SF) retinal imaging is regarded as the gold standard for DR classification as it provides high-quality fundus images. However, it only captures 34% of retina, and is challenging to adopt in clinical settings due to the need for pupil dilation, photographer training and additional grading time. Therefore, other screening methods are often preferred in clinical practice.
Objectives: To determine whether retinal 7SF imaging still provides the most optimal method in DR screening, or if similar results can be achieved by other methods using a smaller field of view (<7SF) or ultra-wide field (UWF) imaging.
Main findings: Of the total 7,168 articles retrieved from databases and other sources, 16 were included in this review. Of the 16 included articles, seven compared ETDRS 7SF with UWF, five compared ETDRS 7SF with <7SF, and the remaining four used other modalities. Compared to 7SF, retinal images of <7SF and UWF both provided satisfactory performance; however, a higher rate of ungradable images in non-mydriatic <7SF modalities may pose a challenge. In conclusion, considering the time-intensive nature of the 7SF method <7SF and UWF could be reasonable options in DR screening.
Methodology: Two reviewers conducted the searches in PubMed, EMBASE and Cochrane Library to identify relevant studies published from inception to 17 March 2020. No geographical filters were applied. The authors reported identifying one additional record from other sources. The articles published in English were included if they were full-text and peer-reviewed publications on patients at least 18 years old and compared DR classification between two standards (preferably 7SF as one of these). The authors first selected the articles based on the title, then conducted abstract screening and finally full-text screening. Two reviewers screened the identified articles.
Applicability/external validity: Authors mentioned that the gold standard of ETDRS 7SF has stood the test of time in DR grading, but other approaches in general have agreements that can be considered moderate, substantial, or almost perfect. In addition, the authors suggest that solutions should be tailored for individual health care systems considering the population of diabetic patients and health care resources available for DR screening.
Geographic focus:
Included studies in the review were conducted in high income settings only. The authors did not explicitly discuss the applicability of their findings to low and middle income countries (LMICs) in their paper. However, they did mention that screening for diabetic retinopathy (DR) is recommended in LMICs, and that different methods of retinal imaging may have different advantages and disadvantages in these settings.
Summary of quality assessment:
A low confidence was attributed to the conclusions of this review due to the identified limitations in the approach used to conduct it. The authors did not avoid publication and language bias in the review. Also, the authors did not report assessing the risk of bias of included studies and if a rigorous approach was implemented when extracting data of included studies.
Publication Source:
Kárason KT, Vo D, Grauslund J, Rasmussen ML. Comparison of different methods of retinal imaging for the screening of diabetic retinopathy: a systematic review. Acta Ophthalmol. 2022 Mar;100(2):127-135. doi: 10.1111/aos.14767. Epub 2021 Feb 2. PMID: 33529402.
Downloadable link https://pubmed.ncbi.nlm.nih.gov/33529402/
© 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.
To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.
You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.
These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.
To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.
To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.